98%
921
2 minutes
20
Background: It is recommended that bariatric surgery candidates undergo psychological assessment. However, no specific instrument exists to assess the psychological well-being of bariatric patients, before and after surgery, and for which all constructs are valid for both genders.
Aims: This study aimed to develop and validate a new psychometric instrument to be used before and after bariatric surgery in order to assess psychological outcomes of patients.
Methods: This is a cross-sectional study that composed of 660 individuals from the community and bariatric patients. BariTest was developed on a Likert scale consisting of 59 items, distributed in 6 constructs, which assess the psychological well-being that influences bariatric surgery: emotional state, eating behavior, quality of life, relationship with body weight, alcohol consumption, and social support. Validation of BariTest was developed by the confirmatory factor analysis to check the content, criteria, and construct. The R statistical software version 3.5.0 was used in all analyses, and a significance level of 5% was used.
Results: Adjusted indices of the confirmatory factor analysis model indicate adequate adjustment. Cronbach's alpha of BariTest was 0.93, which indicates good internal consistency. The scores of the emotional state, eating behavior, and quality of life constructs were similar between the results obtained in the community and in the postoperative group, being higher than in the preoperative group. Alcohol consumption was similar in the preoperative and postoperative groups and was lower than the community group.
Conclusions: BariTest is a reliable scale measuring the psychological well-being of patients either before or after bariatric surgery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462854 | PMC |
http://dx.doi.org/10.1590/0102-672020220002e1682 | DOI Listing |
Osteoporos Int
September 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people living with obesity (PwO).
View Article and Find Full Text PDFDiabetes Obes Metab
September 2025
Department of Minimally Invasive Surgery, Hernias and Abdominal Wall Surgery, People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Gastroesophageal Reflux Disease and Bariatric Metabolic Surgery, Research Institute of General and Minimally Invasive Surgery, Ur
Aims: This randomised controlled trial compared the efficacy of modified laparoscopic sleeve gastrectomy with fundoplication (LSGFD) versus standard laparoscopic sleeve gastrectomy (LSG) in achieving weight loss and alleviating gastroesophageal reflux disease (GERD) in patients with obesity.
Materials And Methods: Eighty patients with obesity (body mass index [BMI] ≥27.5 kg/m with comorbidities or ≥32.
Diabetes Obes Metab
September 2025
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Cureus
August 2025
Internal Medicine, Combined Military Hospital, Muzaffarabad, PAK.
This systematic review evaluates the comparative effectiveness of bariatric surgery versus medical therapy in managing obese patients with type 2 diabetes mellitus (T2DM). A decade-long literature search from January 2014 to January 2024 identified 10 randomized controlled trials (RCTs) involving diverse populations, interventions, and outcomes. The analysis demonstrates that bariatric procedures, such as Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and metabolic surgery, consistently outperform medical interventions, including GLP-1 receptor agonists, SGLT2 inhibitors, and intensive lifestyle modifications, in achieving superior glycemic control, weight reduction, and metabolic improvement.
View Article and Find Full Text PDFCureus
August 2025
Department of Internal Medicine, Hamad Medical Corporation, Doha, QAT.
Peroneal neuropathy is a recognized cause for foot drop, typically following trauma, nerve damage, immobilization, or prolonged external pressure. Recently, rapid weight loss after bariatric surgery has been recognised as a potential cause for peroneal neuropathy. This may be due to the loss of protective fat tissue near the peroneal nerve, increasing its susceptibility to compression.
View Article and Find Full Text PDF